Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -170.7%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $4M | $19M | $3M | $6M | $50M | $21M | $24M | $24M | — | — |
| Enterprise Value | $-3443721 | $-2203752 | $15M | $-177233 | $2M | $44M | $17M | $17M | $20M | — | — |
| P/E Ratio → | -0.21 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.32 | 0.70 | 4.62 | 0.65 | 1.78 | 14.31 | 5.32 | 3.33 | 5.49 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -170.7% | -170.7% | -323.8% | -190.3% | -375.3% | -518.4% | -195.2% | -148.4% | -675.5% | — | -1408.8% |
| ROA | -134.7% | -134.7% | -269.9% | -133.8% | -190.5% | -296.0% | -164.9% | -138.8% | -491.4% | -1224.7% | -228.5% |
| ROIC | — | — | -789.5% | -1399.0% | — | — | — | -1321.6% | -4265.1% | — | -1415.4% |
| ROCE | -164.7% | -164.7% | -203.2% | -171.6% | -245.3% | -433.6% | -196.4% | -142.4% | -405.8% | — | -1377.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.06 | 0.07 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.11 | -0.92 | -0.69 | -1.16 | -1.65 | -1.10 | -0.95 | -0.87 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -8.97 | -6.88 | -42.58 |
Net cash position: cash ($6M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.42 | 4.42 | 4.16 | 4.90 | 2.67 | 2.37 | 3.41 | 14.24 | 18.19 | 0.03 | 0.55 |
| Quick Ratio | 4.42 | 4.42 | 4.16 | 4.90 | 2.67 | 2.37 | 3.41 | 14.24 | 18.19 | 0.03 | 0.55 |
| Cash Ratio | 4.21 | 4.21 | 3.84 | 4.33 | 2.23 | 2.23 | 2.92 | 12.57 | 15.00 | 0.02 | 0.35 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $668630 | $743550 | $56986 | $42521 | $29742 | $19941 | $15764 | $7615 | $8760 | $7645 |
Clinical Trial Funding Shortfall
Based on reported figures, ADIL trades at a price-to-book ratio of 0.32, which suggests the market is heavily discounting the company's intellectual property and clinical potential relative to its historical book value as it navigates the high-risk, pre-revenue phase of its AD04 development program.
The current P/B multiple indicates that investors are assigning little value to the company's assets beyond its immediate cash position. This valuation gap appears to reflect deep skepticism regarding the probability of success for the AD04 program, effectively pricing the equity as a distressed asset rather than a growth-stage biotech platform.
As reported in financial statements, ADIL's ROIC has fluctuated significantly, reaching a low of -198.9% in 2024Q3, which underscores the company's inability to generate positive returns on invested capital while it continues to burn through equity to fund its ongoing clinical trial activities.
The persistent negative ROIC is a structural byproduct of a business model that consumes capital without generating revenue. Investors should monitor whether future clinical milestones can shift this trajectory, as current returns suggest that every dollar of capital deployed is currently eroding shareholder value rather than compounding it.
According to recent SEC filings, ADIL's current ratio has trended downward from 9.48 in 2024Q1 to 3.18 in 2026Q1, indicating that while the company maintains a short-term liquidity cushion, its ability to cover obligations is rapidly diminishing as cash reserves are depleted by clinical development costs.
The decline in the current ratio highlights the narrowing window of operational runway available to management. Without a significant influx of non-dilutive capital or a strategic partnership, the company's liquidity position appears increasingly vulnerable to the ongoing cash burn required to sustain its research and development efforts.
Based on a comparison with micro-cap peers like Matinas BioPharma, ADIL's valuation metrics appear to be structurally aligned with the broader sector's distress, as both companies struggle with negative margins and the inherent difficulty of funding long-duration clinical trials in a challenging capital market environment.
The lack of a meaningful valuation premium over its peers suggests that the market does not yet differentiate ADIL's proprietary genetic screening approach from other speculative biotech assets. This parity warrants further investigation into whether the company's unique therapeutic mechanism is being overlooked or if the market is correctly pricing the shared risk of clinical failure.
As indicated by the company's negative TTM P/E of -0.21, the use of earnings-based valuation multiples is fundamentally misapplied to ADIL, as the firm lacks the revenue and operational maturity required to make traditional profitability metrics a meaningful indicator of its underlying business value or future prospects.
Investors should instead focus on cash-burn metrics and the probability-weighted net present value of the AD04 clinical program. Relying on P/E ratios in a pre-revenue context obscures the reality that the company's value is derived from its intellectual property and clinical data, not its current ability to generate accounting earnings.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADIL stock.
Adial Pharmaceuticals, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Adial Pharmaceuticals, Inc.'s return on equity (ROE) is -170.7%. The historical average is -233.9%.
Based on historical data, Adial Pharmaceuticals, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.